Michel Belley
About
Michel Belley is a scholar working on Organic Chemistry, Molecular Biology and Pharmacology.
According to data from OpenAlex, Michel Belley has authored 40 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Organic Chemistry, 11 papers in Molecular Biology and 10 papers in Pharmacology. Recurrent topics in Michel Belley's work include Asthma and respiratory diseases (8 papers), Asymmetric Synthesis and Catalysis (7 papers) and Inflammatory mediators and NSAID effects (7 papers). Michel Belley is often cited by papers focused on Asthma and respiratory diseases (8 papers), Asymmetric Synthesis and Catalysis (7 papers) and Inflammatory mediators and NSAID effects (7 papers). Michel Belley collaborates with scholars based in Canada, United States and United Kingdom. Michel Belley's co-authors include Kathleen M. Metters, Robert Zamboni, Danielle Denis, Mark Abramovitz, Marc Labelle, Michel Gallant, Sonia Lamontagne, Marie‐Claude Carrière, Nicole Sawyer and Claude Dufresne and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Medicinal Chemistry and Journal of Pharmacology and Experimental Therapeutics.
In The Last Decade
Michel Belley
40 papers receiving 1.6k citations
Peers
Michel Belley
Deborah Slipetz Canada
Susan A. Gregory United States
Philip Tagari Canada
Peter R Bernstein United States
Hiroaki Nomura Japan
Robert N. DeHaven United States
Chi‐Chung Chan Canada
Toichi Takenaka Japan
Kyle P. Chiang United States
Kang Cheng United States
Citations per year, relative to Michel Belley Michel Belley (= 1×)
peers
Deborah Slipetz
Countries citing papers authored by Michel Belley
Since
Specialization
Citations
This map shows the geographic impact of Michel Belley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michel Belley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michel Belley more than expected).
Fields of papers citing papers by Michel Belley
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Michel Belley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michel Belley. The network helps show where Michel Belley may publish in the future.
Co-authorship network of co-authors of Michel Belley
This figure shows the co-authorship network connecting the top 25 collaborators of Michel Belley. A scholar is included among the top collaborators of Michel Belley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michel Belley. Michel Belley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Belley, Michel. (2016). En réponse à …. Larivée, S. (2016). Traité de pensée magique pour jeunes ados. Revue de psychoéducation, 45(1), 211-228. Revue de psychoéducation. 45(1). 227–227.
2.
Han, Yongxin, Michel Belley, Christopher I. Bayly, et al.. (2008). Discovery of [(3-bromo-7-cyano-2-naphthyl)(difluoro)methyl]phosphonic acid, a potent and orally active small molecule PTP1B inhibitor. Bioorganic & Medicinal Chemistry Letters. 18(11). 3200–3205.
3.
Burch, Jason D., Michel Belley, Réjean Fortin, et al.. (2008). Structure–activity relationships and pharmacokinetic parameters of quinoline acylsulfonamides as potent and selective antagonists of the EP4 receptor. Bioorganic & Medicinal Chemistry Letters. 18(6). 2048–2054.
4.
Belley, Michel, Chi Chung Chan, Yves Gareau, et al.. (2006). Comparison between two classes of selective EP3 antagonists and their biological activities. Bioorganic & Medicinal Chemistry Letters. 16(21). 5639–5642.
5.
Urban, M.O., Ke Ren, Ki‐Tae Park, et al.. (2005). Comparison of the Antinociceptive Profiles of Gabapentin and 3-Methylgabapentin in Rat Models of Acute and Persistent Pain: Implications for Mechanism of Action. Journal of Pharmacology and Experimental Therapeutics. 313(3). 1209–1216.
6.
Belley, Michel, Michel Gallant, Bruno Roy, et al.. (2004). Structure–activity relationship studies on ortho-substituted cinnamic acids, a new class of selective EP3 antagonists. Bioorganic & Medicinal Chemistry Letters. 15(3). 527–530.
7.
Gallant, Michel, Michel Belley, Marie‐Claude Carrière, et al.. (2003). Structure–activity relationship of triaryl propionic acid analogues on the human EP3 prostanoid receptor. Bioorganic & Medicinal Chemistry Letters. 13(21). 3813–3816.
8.
Ng, Gordon, Sandrine S. Bertrand, Richard Sullivan, et al.. (2001). γ-Aminobutyric Acid Type B Receptors with Specific Heterodimer Composition and Postsynaptic Actions in Hippocampal Neurons Are Targets of Anticonvulsant Gabapentin Action. Molecular Pharmacology. 59(1). 144–152.
9.
Sullivan, Richard, Anne Châteauneuf, Nathalie Coulombe, et al.. (2000). Coexpression of Full-Length γ-Aminobutyric AcidB(GABAB) Receptors with Truncated Receptors and Metabotropic Glutamate Receptor 4 Supports the GABAB Heterodimer as the Functional Receptor. Journal of Pharmacology and Experimental Therapeutics. 293(2). 460–467.
10.
Abramovitz, Mark, Mohammed Adam, Yves Boie, et al.. (2000). The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1483(2). 285–293.
11.
Belley, Michel, et al.. (1999). Synthesis of the Nanomolar Photoaffinity GABAB Receptor Ligand CGP 71872 Reveals Diversity in the Tissue Distribution of GABAB Receptor Forms. Bioorganic & Medicinal Chemistry. 7(12). 2697–2704.
12.
Black, Shawn C., Christine Brideau, M. Cirino, et al.. (1998). Differential Effect of a Selective Cyclooxygenase-2 Inhibitor Versus Indomethacin on Renal Blood Flow in Conscious Volume-Depleted Dogs. Journal of Cardiovascular Pharmacology. 32(5). 686–694.
13.
Mancini, Joseph A., Russell J. Waugh, John A. Thompson, et al.. (1998). Structural Characterization of the Covalent Attachment of Leukotriene A3to Leukotriene A4Hydrolase. Archives of Biochemistry and Biophysics. 354(1). 117–124.
14.
Prasit, Peppi, Michel Belley, Christine Brideau, et al.. (1993). A new class of leukotriene biosynthesis inhibitor: the development of MK-0591.. PubMed. 6(1-3). 239–44.
15.
Xiang, Yi, et al.. (1993). .alpha.-(Arylsulfonamido)borneols as auxiliaries in asymmetric synthesis: an efficient and highly stereoselective method for the reduction of .alpha.-keto esters. The Journal of Organic Chemistry. 58(5). 993–994.
16.
King, Anthony O., Edward G. Corley, Robert D. Larsen, et al.. (1993). An efficient synthesis of LTD4 antagonist L-699,392. The Journal of Organic Chemistry. 58(14). 3731–3735.
17.
Zamboni, Robert, Michel Belley, Éric Champion, et al.. (1992). Development of a novel series of styrylquinoline compounds as high-affinity leukotriene D4 receptor antagonists: synthetic and structure-activity studies leading to the discovery of (.+-.)-3-[[[3-[2-(7-chloro-2-quinolinyl)-(E)-ethenyl]phenyl][[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]propionic acid. Journal of Medicinal Chemistry. 35(21). 3832–3844.
18.
Jones, Thomas R., Robert Zamboni, Michel Belley, et al.. (1991). Pharmacology of the leukotriene antagonist verlukast: The (R)-enantiomer of MK-571. Canadian Journal of Physiology and Pharmacology. 69(12). 1847–1854.
19.
Prasit, Petpiboon, Michel Belley, Jilly F. Evans, et al.. (1991). A new class of leukotriene biosynthesis inhibitors: The development of ((4-(4-chlorophenyl)-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)acetic acid, L-674,636. Bioorganic & Medicinal Chemistry Letters. 1(11). 645–648.
20.
Jones, Thomas R., Robert Zamboni, Michel Belley, et al.. (1989). Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist. Canadian Journal of Physiology and Pharmacology. 67(1). 17–28.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Deborah Slipetz Breakdown of academic impact, for papers by Susan A. Gregory Breakdown of academic impact, for papers by Philip Tagari Breakdown of academic impact, for papers by Peter R Bernstein Breakdown of academic impact, for papers by Hiroaki Nomura Breakdown of academic impact, for papers by Robert N. DeHaven Breakdown of academic impact, for papers by Chi‐Chung Chan Breakdown of academic impact, for papers by Toichi Takenaka Breakdown of academic impact, for papers by Kyle P. Chiang Breakdown of academic impact, for papers by Kang Cheng